Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short bowel syndrome and oral bioavailability of antibiotics
2021-001468-13Phase 4Active
- Sponsor
- CHRU Nancy
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of amoxicillin, clavulanic acid, levofloxacin, ofloxacin, sulfamethoxazole and 1 more in urinary tract infection (UTI) and short bowel syndrome (SBS) (2 arms), sponsored by CHRU Nancy. Primary endpoint: Absolute oral bioavailability. Started May 2021; status: active.
02
Drugs
amoxicillinclavulanic acidlevofloxacinofloxacinsulfamethoxazole
03
Conditions
urinary tract infection (UTI)short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2021-001468-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001468-13.